Journal of Applied Physiology Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 79: 2122-2131, 1995;
8750-7587/95 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, S. J.
Right arrow Articles by Oparil, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, S. J.
Right arrow Articles by Oparil, S.

Journal of Applied Physiology, Vol 79, Issue 6 2122-2131, Copyright © 1995 by American Physiological Society

ARTICLES

Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats

S. J. Chen, Y. F. Chen, Q. C. Meng, J. Durand, V. S. Dicarlo and S. Oparil
Division of Cardiovascular Disease, University of Alabama at Birmingham 35294, USA.

The current study examined the effects of bosentan, an orally active antagonist of endothelin-A and -B receptors, on the development and maintenance of hypoxia (10% O2)-induced pulmonary hypertension and vascular remodeling in the rat. Pretreatment with bosentan (100 mg.kg-1.day-1, 1 gavage/day for 2 days) completely blocked the pulmonary vasoconstrictor response to acute hypoxia. Chronic bosentan treatment (100 mg.kg-1.day-1 po in the food) instituted 48 h before hypoxic exposure prevented the subsequent development of pulmonary hypertension, attenuated the associated right heart hypertrophy, and prevented the remodeling of small (50-100 microns) pulmonary arteries without altering systemic arterial pressure. Institution of bosentan treatment (for 4 wk) after 2 wk of hypoxia produced a significant reversal of established hypoxia-induced pulmonary hypertension (from 36 +/- 1 to 25 +/- 1 mmHg), right heart hypertrophy, and pulmonary vascular remodeling despite continuing hypoxic exposure. These findings support the hypothesis that endogenous endothelin-1 plays a major role in hypoxic pulmonary vasoconstriction and/or hypertension, right heart hypertrophy, and pulmonary vascular remodeling and suggest that endothelin-receptor blockade may be useful in the treatment of hypoxic pulmonary hypertension humans.


This article has been cited by other articles:


Home page
 ChestHome page
V. Faoro, S. Boldingh, M. Moreels, S. Martinez, M. Lamotte, P. Unger, S. Brimioulle, S. Huez, and R. Naeije
Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia
Chest, May 1, 2009; 135(5): 1215 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
N. P. Talbot, G. M. Balanos, P. A. Robbins, and K. L. Dorrington
Can intravenous endothelin-1 be used to enhance hypoxic pulmonary vasoconstriction in healthy humans?
Br. J. Anaesth., October 1, 2008; 101(4): 466 - 472.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J., August 2, 2008; 29(16): 1936 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. O. Schwenke, T. Tokudome, M. Shirai, H. Hosoda, T. Horio, I. Kishimoto, and K. Kangawa
Exogenous Ghrelin Attenuates the Progression of Chronic Hypoxia-Induced Pulmonary Hypertension in Conscious Rats
Endocrinology, January 1, 2008; 149(1): 237 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr., J. Behr, K. K. Brown, R. M. du Bois, L. Lancaster, J. A. de Andrade, G. Stahler, I. Leconte, S. Roux, and G. Raghu
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 75 - 81.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
J. Dupuis
Endothelin: setting the scene in PAH
Eur. Respir. Rev., August 1, 2007; 16(102): 3 - 7.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Chen, L. He, X. Liu, B. Dinger, L. Stensaas, and S. Fidone
Effect of the endothelin receptor antagonist bosentan on chronic hypoxia-induced morphological and physiological changes in rat carotid body
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1257 - L1262.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
M D'Alto, C D Vizza, E Romeo, R Badagliacca, G Santoro, R Poscia, B Sarubbi, M Mancone, P Argiento, F Ferrante, et al.
Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect
Heart, May 1, 2007; 93(5): 621 - 625.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Maiya, A A Hislop, Y Flynn, and S G Haworth
Response to bosentan in children with pulmonary hypertension
Heart, May 1, 2006; 92(5): 664 - 670.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. Weigand, J. T. Sylvester, and L. A. Shimoda
Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats
Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L284 - L290.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
Heart, November 1, 2005; 91(11): 1447 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Henriques-Coelho, J. Correia-Pinto, R. Roncon-Albuquerque Jr, M. J. Baptista, A. P. Lourenco, S. M. Oliveira, A. Brandao-Nogueira, A. Teles, J. M. Fortunato, and A. F. Leite-Moreira
Endogenous production of ghrelin and beneficial effects of its exogenous administration in monocrotaline-induced pulmonary hypertension
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2885 - H2890.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
P. Li, S. Oparil, W. Feng, and Y.-F. Chen
Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells
J Appl Physiol, October 1, 2004; 97(4): 1550 - 1558.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
N. Suleman and A. E. Frost
Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Hypertension
Chest, September 1, 2004; 126(3): 808 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E Hachulla and J G Coghlan
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. M. Tsai, M. Wang, M. W. Turrentine, Y. Mahomed, J. W. Brown, and D. R. Meldrum
Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies
Ann. Thorac. Surg., July 1, 2004; 78(1): 360 - 368.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest, July 1, 2004; 126(1_suppl): 35S - 62S.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
D. Abraham, K. Krenn, G. Seebacher, P. Paulus, W. Klepetko, and S. Aharinejad
Upregulated hypoxia-inducible factor-1 DNA binding activity to the vascular endothelial growth factor-A promoter mediates increased vascular permeability in donor lung grafts
Ann. Thorac. Surg., May 1, 2004; 77(5): 1751 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
G. L. Semenza
O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1
J Appl Physiol, March 1, 2004; 96(3): 1173 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, S Rammos, Z S Kyriakides, D J Webb, N R Johnston, D V Cokkinos, and D T. Kremastinos
Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease
Heart, October 1, 2003; 89(10): 1221 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
W.-M. Zhang, K.-P. Yip, M.-J. Lin, L. A. Shimoda, W.-H. Li, and J. S. K. Sham
ET-1 activates Ca2+ sparks in PASMC: local Ca2+ signaling between inositol trisphosphate and ryanodine receptors
Am J Physiol Lung Cell Mol Physiol, September 1, 2003; 285(3): L680 - L690.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Sharma
Treatment of Pulmonary Arterial Hypertension: A Step Forward
Chest, July 1, 2003; 124(1): 8 - 11.
[Full Text] [PDF]

Home page
 ChestHome page
O. Sitbon, D. B. Badesch, R. N. Channick, A. Frost, I. M. Robbins, G. Simonneau, V. F. Tapson, and L. J. Rubin
Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study
Chest, July 1, 2003; 124(1): 247 - 254.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. W Kenyon and J. M Nappi
Bosentan for the Treatment of Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2003; 37(7): 1055 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
I. Hubloue, D. Biarent, S. A. Kafi, G. Bejjani, F. Kerbaul, R. Naeije, and M. Leeman
Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction
Eur. Respir. J., January 1, 2003; 21(1): 19 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. V. Remillard, W.-M. Zhang, L. A. Shimoda, and J. S. K. Sham
Physiological properties and functions of Ca2+ sparks in rat intrapulmonary arterial smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L433 - L444.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Chen, L. He, B. Dinger, L. Stensaas, and S. Fidone
Role of endothelin and endothelin A-type receptor in adaptation of the carotid body to chronic hypoxia
Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1314 - L1323.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. J. Rubin, D. B. Badesch, R. J. Barst, N. Galie, C. M. Black, A. Keogh, T. Pulido, A. Frost, S. Roux, I. Leconte, et al.
Bosentan Therapy for Pulmonary Arterial Hypertension
N. Engl. J. Med., March 21, 2002; 346(12): 896 - 903.
[Abstract] [Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
N. H.S. Kim and L. J. Rubin
Endothelin in Health and Disease: Endothelin Receptor Antagonists in the Management of Pulmonary Artery Hypertension
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2002; 7(1): 9 - 19.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
F. Brunner, G. Wolkart, and S. Haleen
Defective Intracellular Calcium Handling in Monocrotaline-Induced Right Ventricular Hypertrophy: Protective Effect of Long-Term Endothelin-A Receptor Blockade with 2-Benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080)
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 442 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. DAVIE, S. J. HALEEN, P. D. UPTON, J. M. POLAK, M. H. YACOUB, N. W. MORRELL, and J. WHARTON
ETA and ETB Receptors Modulate the Proliferation of Human Pulmonary Artery Smooth Muscle Cells
Am. J. Respir. Crit. Care Med., February 1, 2002; 165(3): 398 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Shimoda, J. T. Sylvester, G. M. Booth, T. H. Shimoda, S. Meeker, B. J. Undem, and J. S. K. Sham
Inhibition of voltage-gated K+ currents by endothelin-1 in human pulmonary arterial myocytes
Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1115 - L1122.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. Takahashi, S. Soma, M. Muramatsu, M. Oka, and Y. Fukuchi
Upregulation of ET-1 and its receptors and remodeling in small pulmonary veins under hypoxic conditions
Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1104 - L1114.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
Q. Liu, J. S. K. Sham, L. A. Shimoda, and J. T. Sylvester
Hypoxic constriction of porcine distal pulmonary arteries: endothelium and endothelin dependence
Am J Physiol Lung Cell Mol Physiol, May 1, 2001; 280(5): L856 - L865.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. D. Ivy, I. F. McMurtry, M. Yanagisawa, C. E. Gariepy, T. D. Le Cras, S. A. Gebb, K. G. Morris, R. C. Wiseman, and S. H. Abman
Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction
Am J Physiol Lung Cell Mol Physiol, May 1, 2001; 280(5): L1040 - L1048.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. F. Luscher and M. Barton
Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs
Circulation, November 7, 2000; 102(19): 2434 - 2440.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Shimoda, J. S. K. Sham, T. H. Shimoda, and J. T. Sylvester
L-type Ca2+ channels, resting [Ca2+]i, and ET-1-induced responses in chronically hypoxic pulmonary myocytes
Am J Physiol Lung Cell Mol Physiol, November 1, 2000; 279(5): L884 - L894.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. C. Carpenter and K. R. Stenmark
Endothelin receptor blockade decreases lung water in young rats exposed to viral infection and hypoxia
Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L547 - L554.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. S. K. Sham, B. R. Crenshaw Jr., L.-H. Deng, L. A. Shimoda, and J. T. Sylvester
Effects of hypoxia in porcine pulmonary arterial myocytes: roles of KV channel and endothelin-1
Am J Physiol Lung Cell Mol Physiol, August 1, 2000; 279(2): L262 - L272.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. J. Williamson, L. L. Wallman, R. Jones, A. M. Keogh, F. Scroope, BEd, R. Penny, C. Weber, and P. S. Macdonald
Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension
Circulation, July 25, 2000; 102(4): 411 - 418.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K. Sato, Y. Morio, K. G. Morris, D. M. Rodman, and I. F. McMurtry
Mechanism of hypoxic pulmonary vasoconstriction involves ETA receptor-mediated inhibition of KATP channel
Am J Physiol Lung Cell Mol Physiol, March 1, 2000; 278(3): L434 - L442.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
S. Doi, N. Smedira, and P. A. Murray
Pulmonary vasoregulation by endothelin in conscious dogs after left lung transplantation
J Appl Physiol, January 1, 2000; 88(1): 210 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Shimoda, J. T. Sylvester, and J. S. K. Sham
Mobilization of intracellular Ca2+ by endothelin-1 in rat intrapulmonary arterial smooth muscle cells
Am J Physiol Lung Cell Mol Physiol, January 1, 2000; 278(1): L157 - L164.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. Pearl, S. A. Wellmann, J. L. McNamara, J. P. Lombardi, C. J. Wagner, J. L. Raake, and D. P. Nelson
Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function
Ann. Thorac. Surg., November 1, 1999; 68(5): 1714 - 1721.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Shimoda, J. T. Sylvester, and J. S. K. Sham
Chronic hypoxia alters effects of endothelin and angiotensin on K+ currents in pulmonary arterial myocytes
Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L431 - L439.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. Sartori, L. Vollenweider, B.-M. Loffler, A. Delabays, P. Nicod, P. Bartsch, and U. Scherrer
Exaggerated Endothelin Release in High-Altitude Pulmonary Edema
Circulation, May 25, 1999; 99(20): 2665 - 2668.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Muramatsu, M. Oka, Y. Morio, S. Soma, H. Takahashi, and Y. Fukuchi
Chronic hypoxia augments endothelin-B receptor-mediated vasodilation in isolated perfused rat lungs
Am J Physiol Lung Cell Mol Physiol, February 1, 1999; 276(2): L358 - L364.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Y. Yu, M. G. Frid, L. A. Shimoda, C. M. Wiener, K. Stenmark, and G. L. Semenza
Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung
Am J Physiol Lung Cell Mol Physiol, October 1, 1998; 275(4): L818 - L826.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Hoshino, R. Yamauchi, K. Kikkawa, H. Yabana, and S. Murata
Pharmacological Profile of T-0201, a Highly Potent and Orally Active Endothelin Receptor Antagonist
J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 643 - 649.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
L. A. Shimoda, J. T. Sylvester, and J. S. K. Sham
Inhibition of voltage-gated K+ current in rat intrapulmonary arterial myocytes by endothelin-1
Am J Physiol Lung Cell Mol Physiol, May 1, 1998; 274(5): L842 - L853.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. Dunbar Ivy, T. D. Le Cras, M. P. Horan, and S. H. Abman
Increased lung preproET-1 and decreased ETB-receptor gene expression in fetal pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, April 1, 1998; 274(4): L535 - L541.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
S. P. Gaine, M. A. Hales, and N. A. Flavahan
Hypoxic pulmonary endothelial cells release a diffusible contractile factor distinct from endothelin
Am J Physiol Lung Cell Mol Physiol, April 1, 1998; 274(4): L657 - L664.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. C. Underwood, S. Bochnowicz, R. R. Osborn, M. A. Luttmann, and D. W. P. Hay
Nonpeptide Endothelin Receptor Antagonists. X. Inhibition of Endothelin-1- and Hypoxia-Induced Pulmonary Pressor Responses in the Guinea Pig by the Endothelin Receptor Antagonist, SB 217242
J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1130 - 1137.
[Abstract] [Full Text]

Home page
 HypertensionHome page
J.-P. Gratton, G. Cournoyer, B.-M. Loffler, P. Sirois, and P. D'Orleans-Juste
ETB Receptor and Nitric Oxide Synthase Blockade Induce BQ-123–Sensitive Pressor Effects in the Rabbit
Hypertension, November 1, 1997; 30(5): 1204 - 1209.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
N. S. Hill, R. R. Warburton, L. Pietras, and J. R. Klinger
Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats
J Appl Physiol, October 1, 1997; 83(4): 1209 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. R. FISCHER, D. J. DEYO, H. G. BONE, R. MCGUIRE, L. D. TRABER, and D. L. TRABER
Nitric Oxide Synthase Inhibition Restores Hypoxic Pulmonary Vasoconstriction in Sepsis
Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 833 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S.-H. PARK, D. SALEH, A. GIAID, and R. P. MICHEL
Increased Endothelin-1 in Bleomycin-induced Pulmonary Fibrosis and the Effect of an Endothelin Receptor Antagonist
Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 600 - 608.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
D. D. Ivy, M. Yanagisawa, C. E. Gariepy, S. A. Gebb, K. L. Colvin, and I. F. McMurtry
Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats
Am J Physiol Lung Cell Mol Physiol, April 1, 2002; 282(4): L703 - L712.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online